Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

It has been updated to include the missing portion. NEW YORK – A dual HER2-targeted combination of the antibody-drug conjugate Enhertu (trastuzumab deruxtecan) and the monoclonal antibody Perjeta ...

In the phase III study after a median follow-up of 29 months, patients randomized to T-DXd plus pertuzumab had a median PFS by blinded independent central review of 40.7 months versus 26.9 months ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

On Monday, researchers shared results from a large trial showing Enhertu together with an older drug called Perjeta offer greater benefit in certain tumors than the current first-line standard, which ...